Navigation Links
NxStage(R) Announces Extension of Medisystems Needle Supply and Distribution Agreement
Date:7/21/2009

LAWRENCE, Mass., July 21 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems subsidiary has extended for three years a supply and distribution agreement with Fenwal, Inc. of Lake Zurich, Ill. Medisystems provides needle sets and assemblies to Fenwal, a global medical technology company focused on improving blood collection, separation, safety and availability for patient care. Medisystems products involved in this agreement include the MasterGuard needle sets with FingerShield(TM) safety technology, the leading worldwide needle-stick prevention device.

"Medisystems is delighted to continue its relationship with Fenwal," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. "This agreement provides further validation of our ability to continue to drive steady growth in end-user demand with Medisystems' innovative, high quality, value added product offerings."

MasterGuard Anti-Stick Needle Protector is the only guarded pheresis needle proven to reduce needlestick injuries, as compared to conventional, unguarded needles. Medisystems' patented FingerShield technology helps protect medical technicians' and caregivers' pressure-holding fingers during pheresis procedures. MasterGuard is also designed to allow for optimal visualization of the needle and does not interfere with site selection, cannulation technique or tapedown for patient safety and procedural efficacy during pheresis.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. Medisystems, a wholly owned subsidiary of NxStage, designs, manufactures, imports and distributes innovative medical devices, primarily for use in dialysis and related blood treatments (www.medisystems.com). For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage(R) Announces Medisystems(R) Bloodline Distribution Agreement with Gambro
2. NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloittes 2008 Technology Fast 500
3. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
4. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
5. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
6. The Neutraceutical Company Announces Powerful New Feel-Good Product
7. Domain Registration Corp. Announces Name Change to BioPharm Asia, Inc.
8. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
9. Owensboro Medical Health System Announces Results of Its Modified Dutch Auction Tender Offer
10. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
11. Domain Registration Corp. Announces Name Change to BioPharm Asia, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology: